EV platform technology to select specific binders: in cooperation with BOKU (University of Natural Resources and Life Sciences Vienna) and ACIB (Austrian Center of Industrial Biotechnolgy), Evercyte has generated a technology platform for the development of cell/tissue targeting extracellualr vesicles. This platform is based on the generation of a surface display library by randomization of an extracellular loop of EV surface proteins.
What we need:
soluble, fluorescently labeled antigen-of-interest for selection of binding CD81 mutants for targeting EVs towards cells carrying the specific antigen-of-interest. Timelines:
around 5-8 months to deliver specific antigen binding EVs.
Recent example – generation of tumor-targeting EVs
In order to improve tumor targeting, Evercyte and MDimune have entered a collaboration where Evercyte’s novel and proprietary technology platform will be combined with MDimune´s highly expandable BioDrone® platform for the generation of targeted extracellular vesicles (EVs). Thereby identified high-affinity binders to specific tumor antigens will be used to develop novel drug-targeting vehicles.
Recent example - targeting laminin
Recombinant extracellular vesicles targeting laminin as proof-of-principle enhances cellular uptake of EVs significantly. Please have a look at our new publication "An engineered CD81-based combinatorial library for selecting recombinant binders to cell surface proteins: Laminin binding CD81 enhances cellular uptake of extracellular vesicles." J Extracell Vesicles. 2021;10:e12139.
This work was performed in cooperation with ACIB, University of Natural Resources and Life Sciences, Vienna and the Ludwig Boltzmann Institute for Traumatology – the research center in collaboration with AUVA (LBI Trauma).
Leaflets - extracellular vesicles
(2021). An engineered CD81-based combinatorial library for selecting recombinant binders to cell surface proteins: Laminin binding CD81 enhances cellular uptake of extracellular vesicles. J Am Soc Nephrol. 2011 Jul;22(7):1221-8.